Insiders Nkarta, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
6.79 ^USD	+4.46%		+5.43%	+2.88%

May. 25	Certain Common Stock of Nkarta, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	CI
May. 25	Certain Pre-Funded Warrants of Nkarta, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	CI

Nkarta Names Alyssa Levin as Chief Financial and Business Officer	23-07-05	MT
Nkarta, Inc. Appoints Alyssa Levin as Chief Financial Officer	23-07-05	CI
Nkarta, Inc. Appoints Alyssa Levin as Chief Business Officer	23-07-05	CI
Laura Shawver Announces Not Stand for Re-Election to the Board of Nkarta, Inc	23-04-24	CI
Nkarta CFO Nadir Mahmood Resigns; Trial Update on Prospective Leukemia Treatment Set for Q2; Stock Rises	23-03-30	MT
Nkarta, Inc. Announces Resignation of Nadir Mahmood as Chief Financial and Business Officer	23-03-30	CI
Nkarta Names David Shook as Chief Medical Officer	23-01-09	MT
Nkarta, Inc. Promotes David R. Shook to Chief Medical Officer	23-01-09	CI
Insider Sell: Nkarta	22-09-30	MT
Insider Sell: Nkarta	22-08-17	MT
Insider Sell: Nkarta	22-08-17	MT
Nkarta Appoints Chief Technical Officer, Chief Administrative Officer	22-07-25	MT
Nkarta, Inc. Announces Executive Changes	22-07-25	CI
Nkarta, Inc. Announces Executive Changes	22-05-16	CI
Nkarta, Inc. Appoints Angela M. Thedinga to its Board of Directors	22-03-29	CI
Oyster Point Pharma : Names Donald Santel as Non-Executive Chairman	21-08-03	MT
Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term	21-06-14	GL
Nkarta, Inc. Announces Executive Changes	20-10-05	CI
Nkarta, Inc. Announces Board Appointments	20-04-27	CI
Nkarta Therapeutics Appoints Yvonne Li as Senior Vice President, Finance	19-12-09	CI

No results for this search